Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FASN | P49327 | 8/20 | 0.47 |
| ▸ | ABL1 | P00519 | 3/20 | 0.46 |
| ▸ | BCR | P11274 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | SLC6A7 | Q99884 | 1/20 | 0.40 |
| ▸ | CYP46A1 | Q9Y6A2 | 1/20 | 0.40 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19781185 | 0.83 | ABL1 (0.44) | ABL1BCRSLC6A7TRPV1 | |
| SCHEMBL21480942 | 0.81 | FASN (0.47) | FASN | |
| SCHEMBL18573166 | 0.77 | ABL1 (0.51) | ABL1BCRKDM4ERAB9ASMN1; SMN2 | |
| SCHEMBL9001847 | 0.77 | FASN (0.52) | FASNKDM4E | |
| SCHEMBL19780755 | 0.74 | ALDH1A1 (0.49) | FASNKDM4ERAB9ASMN1; SMN2 | |
| SCHEMBL210344 | 0.73 | DCTPP1 (0.52) | ABL1BCRKDM4ERAB9ASMN1; SMN2 | |
| SCHEMBL21019389 | 0.73 | KDM4E (0.50) | ABL1BCRKDM4ERAB9ASMN1; SMN2 | |
| SCHEMBL31054349 | 0.73 | DCTPP1 (0.52) | ABL1BCRKDM4ERAB9ASMN1; SMN2 | |
| SCHEMBL19781177 | 0.72 | MCHR1 (0.58) | ABL1BCRSLC6A7TRPV1 | |
| SCHEMBL22059856 | 0.72 | ABL1 (0.46) | ABL1BCRKDM4ERAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230322826-A1 | METAL COMPLEXES | UDC IRELAND LIMITED (IE) | 2023-10-12 | — | — | US | disclosed |
| US-20230322826-A1 | METAL COMPLEXES | UDC IRELAND LIMITED (IE) | 2023-10-12 | — | — | US | disclosed |
| US-11713332-B2 | Metal complexes | MERCK PATENT GMBH (DE) | 2023-08-01 | — | — | US | disclosed |
| US-11713332-B2 | Metal complexes | MERCK PATENT GMBH (DE) | 2023-08-01 | — | — | US | disclosed |
| EP-3484868-B1 | METAL COMPLEXES | MERCK PATENT GMBH (DE) | 2020-11-25 | — | — | EP | disclosed |
| US-20190315787-A1 | METAL COMPLEXES | MERCK PATENT GMBH (DE) | 2019-10-17 | — | — | US | disclosed |
| WO-2018011186-A1 | METAL COMPLEXES | MERCK PATENT GMBH (DE) | 2018-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190315787-A1 | METAL COMPLEXES | AP1M1, SOD1, AP3M1 | FASN 3519/4885ABL1 2641/4885BCR 4083/4885 |
| US-11713332-B2 | Metal complexes | AP1M1, SOD1, AP3M1 | FASN 3519/4885ABL1 2641/4885BCR 4083/4885 |
| US-20230322826-A1 | METAL COMPLEXES | AP1M1, SOD1, AP3M1 | FASN 3519/4885ABL1 2641/4885BCR 4083/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.